AASLD 2015

What Factors Increase SVRs with Simeprevir, Peg-IFN, Ribavirin?

A higher dose of ribavirin for treatment-naïve patients receiving simeprevir and pegylated interferon plus ribavirin for chronic hepatitis C virus (HCV) genotype 1, and extended treatment for patients who have not previously responded to treatment, can increase rates of sustained virologic response (SFR), according to data presented at The Liver Meeting® 2015.

‘Real-Life’ Anemia with Boceprevir: No Impact on SVR

Previously-untreated patients with hepatitis C virus (HCV) genotype 1 (GT1) undergoing triple therapy with pegylated interferon, ribavirin, and boceprevir in a “real-word” setting had a 37% frequency rate of anemia, and previously-treated patients have a 40% anemia rate, which can be effectively managed with ribavirin dose reductions, according to authors of an observational study in Germany, presented during The Liver Meeting® 2015.

Low Vitamin D Levels Not Predictive of SVR12 Rates

Although low levels of 25-OH vitamin D are associated with an advanced level of fibrosis in hepatitis C virus (HCV) infection, such levels are not predictive for rates of sustained virologic response at 12 weeks (SVR12), a prospective study presented at The Liver Meeting® 2015 concluded.